Introduction
Clinical islet transplantation is being offered currently to a subset of approximately 15% of patients with type 1 diabetes (T1DM) with refractory hypoglycemia or marked glycemic lability, which cannot be corrected by other means including intensive insulin, improved monitoring, insulin pump therapies, or continuous glucose monitoring systems (CGMS). Objective selection criteria include a Clark Score of less than 4, Hypoglycemia Score of at least 1000, Lability Index of less than 400, or a combination of these variables. With over 750 islet transplants performed in over 30 international centers, this therapy is steadily transferring from research to a standard recognized clinical therapy. Islet transplantation is also being offered after kidney transplantation, where justification is simpler as the patients already require lifelong immunosuppression, and the intraportal islet implantation procedure is a simple nonsurgical intervention with relatively low risk. Currently, islet transplantation offers a highly effective means to restore endogenous, regulated insulin secretion thereby stabilizing glycemic control, preventing hypoglycemia, and corrects hemoglobin A1C (HbA1C) to a level predicted to prevent and reverse chronic, secondary complications of diabetes. The trade-off in terms of lifelong need for immunosuppressive therapies can readily be justified in this setting, but not for patients with otherwise good glycemic control and not routinely for children at this time.
Islet transplantation will only transition further from therapy for few to a cure for all with T1DM once islet transplantation becomes more readily available, means to expand the islet donor supply through expansion of existing islets, stem cell approaches or xenotransplant sources become available, but the remaining challenge of inducing immunological tolerance, preventing islet destruction from recurrence of autoimmunity or alloimmune rejection and avoiding all potential side-effects from immunosuppressive therapies, will all need to be addressed to further this transition.
Purpose of review
The current review addresses a critical need in clinical islet transplantation, namely the routine transition from the requirement of two to four donors down to one donor per recipient. The ability to achieve single-donor islet transplantation will provide many more islet grafts for treatment of an ever-expanding patient base with type 1 diabetes (T1DM) with poor glycemic control. Avoiding exposure of recipients to multiple different donor human leukocyte associated (HLA) antigens is critical if risk of donor sensitization is to be avoided. This point is important as further islet or pancreas transplants in the remote future or the potential future need for a solid organ kidney transplant may become prohibitive if the recipient is sensitized.
Recent findings
This review addresses systematically all areas that contribute to the success or failure of single-donor islet engraftment, beginning with donor-related factors, optimizing islet isolation and culture conditions, and describes a series of strategies in the treatment of the recipient to prevent inflammation, apoptosis, islet thrombosis, and improve metabolic functional outcome, all of which will lead to improved single-donor engraftment success. Summary If single-donor islet transplantation can be achieved routinely, therapy will become more widely available, more accepted by the transplant community (currently pancreas transplantation requires only a single donor), and this situation will have a major impact overall as an effective treatment option in T1DM.
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Improving access to human pancreas donors
The starting material for any clinical islet transplant procedure is a pancreas retrieved from either a heartbeating, brain dead organ donor, or a donor that has succumbed after cardiac death (deceased cardiac death; DCD). The use of more marginal pancreas donors is associated with less successful islet yield and potency, but unfortunately, the majority of available organ donors fall into the marginal category. Nonetheless, several groups have made remarkable progress with the use of marginal pancreas donors, and notably the Philadelphia and other groups have had success with single-donor engraftment with DCD pancreas organs [2]. Livingdonor islet transplant has been promoted by the Kyoto group by distal pancreatectomy from mother to daughter, and interestingly a half pancreas islet preparation was sufficient to achieve a sustained period of insulin independence and excellent glycemic control in the recipient [3] . The potential downside is that the donor must face a major surgical intervention, and even if completed laparoscopically, there are risks of surgical diabetes in the donor and potential risks from pancreatic fistula or infection, making this an unpalatable approach for many recipients.
Improving islet isolation success
Extracting large numbers of viable, potent human islets from a donor organ pancreas is a challenging and intensive process that requires considerable expertise, access to unique reagents, including unstable and variable preparations of collagenase enzymes, and access to ultra-clean room facilities that comply with good manufacturing practice (cGMP). The pancreatic duct is cannulated and collagenase enzyme solutions are perfused to the pancreatic islet-acinar interface to help cleave the islets from their exocrine pancreatic bed. The pancreas is then chopped placed within a Ricordi chamber and enzyme solution is circulated as the pancreatic fragments are shaken against a 500 mm screen and marbles. This system was developed by Ricordi et al. [4] , and despite being developed over 20 years ago, remains the established technique for clinical islet isolation. Conversion rates from pancreas processing to clinical transplantation are variable, but most transplant approximately 50%, while discarding preparations that fail to provide sufficient yield to meet a 5000 islet equivalents (IEQ) per kilogram, based on the recipient weight. It is anticipated that the total islet mass required may decrease over time, if some of the innovations discussed below prove to be effective. If the threshold for clinical transplantation were reduced to 2000 IEQ/kg then this situation would immediately improve the isolation to transplant ratio from 50 up to 90% or more, which would have a dramatic impact on clinical transplantation activity.
One of the challenges for approval of islet transplantation as a routine treatment is the lack of a reliable and predictive potency assay. It is well recognized that the insulin stimulation index represents only a crude demonstration of a particular islet product to secrete insulin, the membrane integrity dye exclusion methods are
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insensitive, and alternative approaches including calcium flux analysis, oxygen consumption rate, and other innovative approaches are being developed [5] . The Food and Drug Administration (FDA) have indicated to the islet transplant community that a simple and reliable predictive potency assay remains one of the highest priorities if islet transplantation moves forward from research to clinical approval and Biological Licensure in the USA.
Innovations during islet culture including additives such as insulin-like growth factor 2 (IGF-2) and improving oxygen delivery to islets during culture with breathable membranes may further protect islets from damage [6] .
Improving islet engraftment in the recipient
Achieving single-donor islet engraftment success requires a critical interaction between final implanted islet mass and several recipient factors, including recipient insulin requirement and sensitivity. Typically, single-donor islet engraftment success is easier to achieve in recipients with low baseline insulin requirements (<0.5 U/kg per day insulin). Currently, the intrahepatic portal venous site is the only site that has routinely resulted in insulin independence in the clinic. Development of future, alternative islet implantation sites may allow other sites to achieve or further improve on islet engraftment if engineered appropriately. The degree of activation of the recipient's autoimmune and alloimmune systems may create potent and occasionally insurmountable barriers to successful islet engraftment and early survival.
We will now review a series of different approaches in the recipient's treatment that may favor islet potency, survival and function leading to improved single-donor success.
Anti-inflammatory
When islets are embolized into the portal system, islets become trapped in the terminal portal venous radical branches, become coated with blood clot and, through process of healing, undergo revascularization from the recipient hepatic arterial system. Prior to successful angiogenesis, islets remain ischemic, inflamed, and are subject to apoptosis and necrosis. Several strategies are being developed to suppress inflammation, facilitate neovascularization, and improve single-donor success. Hering et al. [7, 8] defined a series of strategies that improved singledonor islet transplant success at their center, including careful donor and recipient selection, potent T-cell depletion with thymoglobulin or a nondepleting OKT3ala-ala antibody. Koh et al. [9 ] in Edmonton investigated the impact of peritransplant insulin and heparin and, in our own experience, found that single-donor islet transplant success rate rose from 10 to 40%. This paper is one of the first clinical papers to support an extensive scientific contribution by Korsgren and the Uppsala Group to address means of preventing the instant blood mediated inflammatory response (IBMIR) [10] .
Tumor necrosis factor-alpha (TNF-a) represents one of the most dominant targets in acute inflammatory injury of islets. Xenos et al. [11] initially demonstrated the potential benefit of TNF-a blockade in islet transplantation in mice. Hering et al. [8] incorporated this TNF-a strategy using etanercept in their single-donor center experience, with the first dose given intravenously (50 mg) before transplant and repeated subcutaneously 25 mg on days 3, 7, and 10 [9 ] . Unraveling the secrets of single-donor success, especially in terms of understanding the contributions of various factors represents a considerable challenge [12] .
Other novel anti-inflammatory targets include Anakinra, which is an interleukin-1-receptor antagonist (IL1-Ra).
Matsumoto et al. [13 ] have had limited clinical experience in three patients using the IL1-Ra antibody, suggesting that this might confer additional benefit. We have investigated the combination of anti-TNF-a and IL1-Ra blockade with both etanercept and anakinra in marginal mass islet transplant models of human islets in immunodeficient mice, and found this combination to be synergistic in promoting engraftment.
Anti-apoptosis and anti-instant blood mediated inflammatory response strategies
We have extensively investigated strategies to switch off the apoptosis pathways in transplanted human, mouse, and pig islets as a means to promote single-donor islet transplantation success because apoptosis appears to be one of the most dominant targets for modifiable survival of islets after transplantation. Emamaullee et al. [14] first showed engineering of human islets with viral vectors targeting XIAP and demonstrated that XIAP could substantially improve islet survival in mice. We recognized that the use of an adenoviral vector was not a palatable approach for safe clinical application, and searched for molecular drug targets that might serve to block the pancaspase. We recently investigated a compound IDN6556 (Conatus Pharmaceuticals Inc., San Diego, USA), which led to marked improvement in marginal mass engraftment [15 ] . We further tested IDN6556 in a large animal pig autograft model and found similar findings. The addition of a pan-caspase inhibitor led to routine reversal of the diabetic state with marginal mass transplantation of between 10 and 30% of the usual minimal islet transplant mass required to reverse diabetes. If the mouse and pig findings extrapolate to the clinic, we anticipate that this approach will substantially lower the required basal islet transplant mass needed to secure full insulin independence, improve metabolic reserve, reduce risk of donorrelated sensitization from dying islets, and may facilitate the induction of immunological tolerance.
Korsgren's team from Uppsala, Sweden has developed a substantial body of preclinical data to suggest that IBMIR is a major potential target to reduce inflammation and improve islet survival after transplantation. High expression of tissue factor on the surface of human islets leads to platelet aggregation, activation and islet injury. This group has developed several potential targets to therapeutically manipulate the IBMIR response, including the use of dextran sulphate, or surface binding of heparin to the islets to abrogate IBMIR [16, 17] .
Metabolic and growth stimulation strategies
The use of glucagon-like-peptide 1 (GLP1) analogues currently used in the management of patients with T2DM has shown remarkable promise in the setting of single-donor clinical islet transplantation. The Universities of Illinois, Miami, and British Columbia have all demonstrated that the short-acting GLP-1 analogue, exenatide, can facilitate single-donor islet engraftment [18] [19] [20] [21] . Although the addition of exenatide can improve metabolic function, administration is associated with intolerable nausea in 30%. We have explored a related compound, Liraglutide (NovoNordisk, Bagsvaerd, Denmark), a long-acting GLP-1 analogue, with substantially reduced risk of nausea. We found that Liraglutide could promote single-donor islet engraftment in mice, improved early engraftment, and enhanced survival of human islets in culture [22] [23] [24] . Potential alternative strategies using dipeptylpeptidase 4 (DPP-4) inhibitors such as sitagliptin in islet transplantation are also being explored in separate trials. Again, it seems unlikely that these strategies alone will not result in routine singledonor islet transplant engraftment but rather will require a multimodal approach to maximize the potential engraftment and expansion of a limited initial islet mass.
Recipient immunosuppression strategies to facilitate single-donor engraftment
Effective control of both autoimmune and alloimmune pathways remain an essential prerequisite for transplant success. Unfortunately, many of the compounds used to prevent rejection and control autoimmunity are also locally toxic to the islet graft [25, 26] . Elimination of tacrolimus may facilitate metabolic function, but also increases risk of rejection. More recently, the use of T-depletional immunosuppression can substantially improve long-term islet graft survival. Up to five clinical islet transplant groups including our own, the universities of Geneva, and Lille, in France and Minnesota, and San Francisco, in the USA and other groups have now routinely achieved rates of up to 50% insulin independence beyond 5 years after transplantation in islet-alone grafts, results which now match the results of pancreas-alone transplantation, at least within the international pancreas transplant registry for pancreasalone grafts. In Edmonton, Canada we have been exploring alemtuzumab, an anti-CD52 antibody that potently depletes T-cells, and found robust, durable insulin independence beyond 5 years, in a cohort of almost 30 subjects, and that this approach ameliorates both autoallo-and autoimmune reactivity. We have combined this therapy with tacrolimus and CellCept (Roche Canada, Mississauga, Ontario, Canada), but have not been able to achieve high rates of single-donor islet engraftment success with that approach alone, to date.
A number of exciting and novel immunosuppressive targets are emerging with direct clinical application that may facilitate elimination of tacrolimus from the immunosuppressive regimen. The combination of potent T-depletion with sirolimus and CellCept is one option, but may not provide sufficient maintenance of chronic immunosuppression to prevent immune destruction. The use of co-stimulation blockade, using belatacept which blocks co-stimulation signaling through the CD80-CD86 pathways, has shown considerable promise in clinical renal transplantation, and is presently being explored in Emory and Edmonton (CIT/NIH trial). It remains to be seen whether co-stimulation blockade alone and calcineurin-inhibitor free maintenance will be sufficient to prevent rejection events. Recently, the University of San Francisco group reported on remarkable successful outcomes when belatacept co-stimulation blockade is combined with thymoglobulin T-cell depletion [27] . This strategy has allowed for a calcineurin-inhibitor free maintenance strategy and has markedly improved single-donor islet engraftment success in selected cases. Additionally, this group has studied the potential benefit of an anti-LFA-1 antibody called efalizumab in clinical islet transplantation. When combined with thymoglobulin, again this has allowed for tacrolimus-free maintenance immunosuppression and good clinical outcome, but unfortunately, the antibody is on clinical hold due to small but increased risk of progressive multifocal leukoencephalopathy (PML).
Conclusion
Remarkable progress has occurred in clinical islet transplantation over the past 12 years. Before this time, routine insulin independence was almost impossible to achieve. The Edmonton Protocol promoted by our group in 2000 brought unparalleled attention as all seven of the first treated subjects achieved and maintained insulin independence at the time of the report. We subsequently found evanescent rates of insulin independence dwindling to around 10% at 5 years. This has subsequently improved considerably with the use of T-depletional induction therapies and more potent maintenance immunosuppressive strategies based upon use of tacrolimus, and currently at least five centers report rates of insulin independence at 5 or more years after transplant exceeding 50%, rates that currently match the registry data of pancreas-alone transplantation. Routine attainment of single-donor islet transplant success remains an achievable and extremely important goal in islet transplantation. This situation would allow for many more subjects to be treated with islets, and would reduce the potential risk of donor HLAsensitization by avoiding a need to expose recipients to multiple donors. At the present time in our own center and in most other international centers (with the exception of Minnesota, San Francisco, and the University of Illinois, Chicago, USA), at least two islet infusions are required to maintain insulin independence. Moving from multipledonor to single-donor success will require a multimodal approach, including optimization of donor pancreas organs, protection of islets from cold and warm ischemic injury and the injurious process of islet isolation, access to effective, stable and consistent human compatible collagenase enzyme blends for digestion, and several multimodal strategies for treatment of the recipient to suppress immunological, inflammatory and thrombosis pathways, whereas at the same time stimulating neovascularization and metabolic function of the islet graft. Such a multimodal approach will no doubt transform short-and longterm islet transplantation success and will continue to facilitate the rapid transition from research to routine clinical care for this exciting and effective cellular treatment therapy for diabetes.
